Nanoscope Therapeutics Will Present Data in New Orleans

The biotech firm will showcase retinal therapy trial results at the American Academy of Ophthalmology 2026 meeting.

Updated on Oct. 6, 2026 in Biotech

Isometric editorial illustration of a glass magnifying lens on a polished metal surface, representing medical innovation and retinal therapeutic research. — Nanoscope Therapeutics plans to share four-year clinical trial data for its retinal therapy during the American Academy of Ophthalmology meeting in New Orleans. AI Illustration. Upload story photo >

Nanoscope Therapeutics will participate in the American Academy of Ophthalmology 2026 meeting in New Orleans, held October 8-13, 2026. The firm will present four-year REMAIN trial data during the event.

Why it matters

The company's presentation of long-term trial results at this major ophthalmology gathering highlights ongoing progress in developing therapies for retinal degeneration. These updates provide critical visibility into the efficacy of MOGENRY and other innovations for treating vision loss.

The company will present four-year REMAIN data derived from its RESTORE Phase 2b/3 trial.

The players

Nanoscope Therapeutics

This Dallas-based biotechnology company focuses on developing gene therapies to treat patients suffering from retinal degenerative diseases.

Dr. Sam Barone

He serves as the Chief Medical Officer at Nanoscope Therapeutics, overseeing the clinical development of the company's proprietary retinal therapies.

The details

Nanoscope Therapeutics will join the Emerging Innovations in Retinal Therapies panel at the Eyecelerator 2026 conference. Additionally, the company will present an update on MOGENRY and a scientific poster regarding dry AMD during the academy meeting.

The American Academy of Ophthalmology 2026 meeting is scheduled for October 8-13, 2026.

The Big Picture

The presentation of the RESTORE Phase 2b/3 trial data follows a pattern set by major ophthalmic gene therapy research programs. This update marks a significant point in the evaluation of long-term treatment durability for patients with retinal degeneration.

The data release offers insights into potential future treatment options for individuals living with retinal degeneration. Patients and providers should monitor these findings for updates on when such therapies might become accessible for clinical use.

The takeaway

Advancements in retinal gene therapy require consistent long-term data collection to demonstrate sustained patient benefits. Clinical meeting presentations serve as vital venues for the medical community to review these outcomes before wider adoption.